Carsten U Niemann
Overview
Explore the profile of Carsten U Niemann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
2139
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chong S, Lu J, Valentin R, Lehmberg T, Eu J, Wang J, et al.
Mol Cancer
. 2025 Mar;
24(1):62.
PMID: 40025512
Background: Established genetic biomarkers in chronic lymphocytic leukemia (CLL) have been useful in predicting response to chemoimmunotherapy but are less predictive of response to targeted therapies. With several such targeted...
2.
Kyvsgaard E, Grauslund M, Sjo L, Melchior L, Grantzau T, Gjerdrum L, et al.
Am J Hematol
. 2025 Jan;
100(4):712-716.
PMID: 39865309
No abstract available.
3.
Pavlova S, Malcikova J, Radova L, Bonfiglio S, Cowland J, Brieghel C, et al.
Hemasphere
. 2025 Jan;
9(1):e70065.
PMID: 39840379
In chronic lymphocytic leukemia, the reliability of next-generation sequencing (NGS) to detect variants ≤10% allelic frequency (low-VAF) is debated. We tested the ability to detect 23 such variants in 41...
4.
Brieghel C, Petersen S, Brown P, Niemann C
Haematologica
. 2024 Oct;
110(3):768-771.
PMID: 39415686
No abstract available.
5.
Husby S, Tulstrup M, Harslof M, Nielsen C, Haastrup E, Ebbesen L, et al.
Leukemia
. 2024 Sep;
38(11):2456-2465.
PMID: 39223296
Mosaic chromosomal alterations (mCAs) in hematopoietic cells increase mortality and risk of hematological cancers and infections. We investigated the landscape of mCAs and their clinical consequences in 976 patients with...
6.
Simon F, Ligtvoet R, Robrecht S, Cramer P, Kutsch N, Furstenau M, et al.
J Clin Oncol
. 2024 Aug;
43(4):381-391.
PMID: 39213466
Purpose: Surrogate end points are commonly used to estimate treatment efficacy in clinical studies of chronic lymphocytic leukemia (CLL). This patient- and trial-level analysis describes the correlation between progression-free survival...
7.
Furstenau M, Kater A, Robrecht S, von Tresckow J, Zhang C, Gregor M, et al.
Lancet Oncol
. 2024 May;
25(6):744-759.
PMID: 38821083
Background: In the primary analysis report of the GAIA/CLL13 trial, we found that venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib improved undetectable measurable residual disease (MRD) rates and progression-free survival compared with chemoimmunotherapy in...
8.
Malcikova J, Pavlova S, Baliakas P, Chatzikonstantinou T, Tausch E, Catherwood M, et al.
Leukemia
. 2024 May;
38(7):1455-1468.
PMID: 38755420
In chronic lymphocytic leukemia (CLL), analysis of TP53 aberrations (deletion and/or mutation) is a crucial part of treatment decision-making algorithms. Technological and treatment advances have resulted in the need for...
9.
Faitova T, Coelho M, da Cunha-Bang C, Ozturk S, Kartal E, Bork P, et al.
Haematologica
. 2024 May;
109(10):3237-3250.
PMID: 38721725
The gut microbiota plays a critical role in maintaining a healthy human body and its dysregulation is associated with various diseases. In this study, we investigated the influence of gut...
10.
Faitova T, Brieghel C, Eriksson F, Niemann C
Hemasphere
. 2024 Mar;
8(3):e57.
PMID: 38505245
No abstract available.